Showing results (81-90 of 96) with videos related to
Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2009
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancerChristine A Iacobuzio-Donahue, Baojin Fu, Shinichi Yachida, et al.The American Journal of Surgical Pathology|January 19, 2012
Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumorsShinichi Yachida, Efsevia Vakiani, Catherine M White, et al.Cancer Medicine|December 27, 2019
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancerMark Yarchoan, Chiung-Yu Huang, Qingfeng Zhu, et al.The New England Journal of Medicine|October 18, 2013
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineDaniel D Von Hoff, Thomas Ervin, Francis P Arena, et al.Nature Communications|June 23, 2026
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trialHejia Henry Wang, Amanda L Huff, S Daniel Haldar, et al.Nature Communications|June 20, 2023
A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinomaThatcher Heumann, Carol Judkins, Keyu Li, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2009
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancerAmanda Blackford, Oscar K Serrano, Christopher L Wolfgang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancerEric S Christenson, Won Jin Ho, Daniel Shu, et al.Journal for Immunotherapy of Cancer|April 21, 2026
Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinomaHoward L Li, Soren Charmsaz, Benjamin J Reisman, et al.Biorxiv : the Preprint Server for Biology|October 31, 2023
Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockadeDaniel H Shu, Won Jin Ho, Luciane T Kagohara, et al.Pageof 10